Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) major shareholder Proquest Investments Iv, L.P. sold 153,830 shares of Eagle Pharmaceuticals stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $79.29, for a total value of $12,197,180.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Proquest Investments Iv, L.P. also recently made the following trade(s):

  • On Monday, November 7th, Proquest Investments Iv, L.P. sold 5,030 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $75.39, for a total value of $379,211.70.
  • On Friday, November 4th, Proquest Investments Iv, L.P. sold 245,770 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $71.02, for a total value of $17,454,585.40.
  • On Friday, September 30th, Proquest Investments Iv, L.P. sold 22,100 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.06, for a total transaction of $1,548,326.00.
  • On Thursday, September 29th, Proquest Investments Iv, L.P. sold 77,900 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.04, for a total transaction of $5,456,116.00.
  • On Wednesday, September 21st, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $66.17, for a total transaction of $6,603,435.15.
  • On Thursday, September 8th, Proquest Investments Iv, L.P. sold 70,925 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $62.50, for a total transaction of $4,432,812.50.
  • On Wednesday, August 24th, Proquest Investments Iv, L.P. sold 28,870 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $63.00, for a total transaction of $1,818,810.00.
  • On Tuesday, August 16th, Proquest Investments Iv, L.P. sold 60,150 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $61.67, for a total transaction of $3,709,450.50.
  • On Monday, August 15th, Proquest Investments Iv, L.P. sold 24,949 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $60.77, for a total transaction of $1,516,150.73.
  • On Wednesday, August 17th, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $61.36, for a total transaction of $6,123,421.20.

Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) opened at 84.22 on Friday. The firm has a market cap of $1.32 billion, a P/E ratio of 431.90 and a beta of 1.37. Eagle Pharmaceuticals Inc. has a 12-month low of $33.02 and a 12-month high of $102.48. The company has a 50-day moving average of $67.18 and a 200 day moving average of $53.43.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.12. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. The company had revenue of $37.80 million for the quarter, compared to analyst estimates of $41.04 million. During the same period in the prior year, the business posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 563.2% compared to the same quarter last year. Equities research analysts anticipate that Eagle Pharmaceuticals Inc. will post $3.13 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

EGRX has been the topic of a number of research reports. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, July 22nd. Mizuho raised shares of Eagle Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $62.00 to $78.00 in a research note on Thursday, November 3rd. RBC Capital Markets reissued an “outperform” rating and issued a $93.00 target price (up from $80.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 3rd. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $91.00 price target on shares of Eagle Pharmaceuticals in a research report on Saturday, October 15th. Finally, William Blair lifted their price target on shares of Eagle Pharmaceuticals from $83.00 to $97.00 and gave the company an “outperform” rating in a research report on Wednesday, November 2nd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Eagle Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $90.24.

A number of hedge funds and other institutional investors have recently modified their holdings of EGRX. State Street Corp raised its position in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. State Street Corp now owns 629,493 shares of the specialty pharmaceutical company’s stock valued at $25,489,000 after buying an additional 246,262 shares during the last quarter. Cormorant Asset Management LLC raised its stake in Eagle Pharmaceuticals by 25.0% in the first quarter. Cormorant Asset Management LLC now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $20,250,000 after buying an additional 100,000 shares in the last quarter. LaSalle Street Capital Management LLC acquired a new stake in Eagle Pharmaceuticals during the second quarter valued at approximately $304,000. Bank of Montreal Can acquired a new stake in Eagle Pharmaceuticals during the second quarter valued at approximately $5,356,000. Finally, American Century Companies Inc. raised its stake in Eagle Pharmaceuticals by 6.1% in the second quarter. American Century Companies Inc. now owns 114,901 shares of the specialty pharmaceutical company’s stock valued at $4,457,000 after buying an additional 6,567 shares in the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.